Lucid Diagnostics wins Concert coverage policy for EsoGuard esophageal DNA test across client health plans

Lucid Diagnostics secured a commercial coverage policy from Concert for its EsoGuard esophageal DNA test, effective July 2026.

Concert cited published guidelines and peer-reviewed evidence, classifying EsoGuard as medically necessary for patients meeting ACG screening criteria.

Multiple Concert client health plans have adopted the policy, expanding potential reimbursement access across those plans.